{"id":"rabeprazloe-bismuth-amoxicillin-clarithromycin","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"5-10","effect":"Taste disturbance"},{"rate":"3-8","effect":"Headache"},{"rate":"1-3","effect":"Allergic reactions (amoxicillin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabeprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an inhospitable environment for H. pylori. Bismuth acts as a bactericidal agent that damages the bacterial cell wall and inhibits urease enzyme. Amoxicillin and clarithromycin are antibiotics that inhibit bacterial protein synthesis and cell wall formation, working synergistically to eliminate the pathogen.","oneSentence":"This quadruple therapy combination eradicates Helicobacter pylori by suppressing gastric acid, disrupting bacterial cell walls, and inhibiting protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:39.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication in peptic ulcer disease"},{"name":"H. pylori-associated chronic gastritis"}]},"trialDetails":[{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rabeprazloe+bismuth+amoxicillin+clarithromycin","genericName":"Rabeprazloe+bismuth+amoxicillin+clarithromycin","companyName":"Xijing Hospital of Digestive Diseases","companyId":"xijing-hospital-of-digestive-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This quadruple therapy combination eradicates Helicobacter pylori by suppressing gastric acid, disrupting bacterial cell walls, and inhibiting protein synthesis. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}